Life Edit Therapeutics
Alan Cabrera is a Scientist I at Life Edit Therapeutics, with ongoing experience as a Doctoral Student in the Hilton Lab at Rice University since November 2018. Cabrera's research focuses on epigenetic engineering, including the design and validation of a modular CRISPR activation system utilizing transient transfection and lentiviral transduction techniques. Previous experience includes a role as a Postbaccalaureate Research Assistant at the University of Washington’s Center for Reproducible Biomedical Modeling, where Cabrera developed computational methods for generating gene regulatory networks, and as an Undergraduate Research Assistant in the Seelig Lab, exploring the relationship between 5' UTR and transcription. Cabrera holds a Bachelor of Science in Bioengineering from the University of Washington and is pursuing a Doctor of Philosophy in Bioengineering and Biomedical Engineering at Rice University.
Life Edit Therapeutics
Life Edit, an ElevateBio company, is a next-generation genome editing company that has built a highly innovative platform with one of the world’s largest and most diverse collections of novel RNA-guided nucleases (RGNs) and base editors. The platform allows Life Edit to target any genomic sequence and develop novel human therapeutics for the most challenging genetic diseases by enabling ex vivo engineering for cell therapies and regenerative medicines and in vivo delivery of gene therapies. In addition to developing its own pipeline of cell and gene therapies, Life Edit Therapeutics will continue to strengthen its platform of genome-editing enzymes, provide gene-editing expertise to strategic partners, and form other third-party partnerships to discover and develop new therapies.